BridgeBio Pharma Cash on Hand 2018-2024 | BBIO

BridgeBio Pharma cash on hand from 2018 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
BridgeBio Pharma Annual Cash on Hand
(Millions of US $)
2023 $452
2022 $510
2021 $837
2020 $607
2019 $546
2018 $436
2017 $
BridgeBio Pharma Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $587
2024-03-31 $520
2023-12-31 $452
2023-09-30 $560
2023-06-30 $404
2023-03-31 $517
2022-12-31 $510
2022-09-30 $592
2022-06-30 $716
2022-03-31 $671
2021-12-31 $837
2021-09-30 $600
2021-06-30 $838
2021-03-31 $919
2020-12-31 $607
2020-09-30 $711
2020-06-30 $841
2020-03-31 $905
2019-12-31 $546
2019-09-30 $536
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00